Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.81% | 1.87% | 1.10% | -1.33% | -0.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.81% | 1.87% | 1.10% | -1.33% | -0.76% |
| Cost of Revenue | 4.24% | 9.65% | 10.12% | 9.13% | 8.51% |
| Gross Profit | 0.59% | -1.83% | -3.00% | -5.96% | -4.86% |
| SG&A Expenses | -0.55% | -0.87% | -1.00% | -2.40% | -1.10% |
| Depreciation & Amortization | -0.28% | 0.17% | -0.61% | -4.44% | -4.67% |
| Other Operating Expenses | 84.79% | -64.97% | -128.28% | -51.84% | -68.66% |
| Total Operating Expenses | 1.20% | 0.28% | -0.06% | 1.13% | 1.55% |
| Operating Income | 6.42% | 13.86% | 8.58% | -16.76% | -15.23% |
| Income Before Tax | 177.19% | 39.74% | 23.08% | -88.07% | -85.15% |
| Income Tax Expenses | 172.80% | 194.75% | -465.40% | -269.48% | -233.15% |
| Earnings from Continuing Operations | -30.01% | 7.55% | 37.69% | -55.22% | -56.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -58.04% | -60.63% | -70.50% | -538.31% | -485.59% |
| Net Income | -30.09% | 7.52% | 37.67% | -55.27% | -56.59% |
| EBIT | 6.42% | 13.86% | 8.58% | -16.76% | -15.23% |
| EBITDA | 1.86% | 6.10% | 4.76% | -7.23% | -5.97% |
| EPS Basic | -30.61% | 6.34% | 35.82% | -55.73% | -56.87% |
| Normalized Basic EPS | 6.12% | 36.35% | 21.93% | -15.37% | -22.45% |
| EPS Diluted | -32.06% | 5.32% | 35.82% | -55.75% | -56.75% |
| Normalized Diluted EPS | 5.03% | 35.23% | 21.34% | -15.29% | -22.22% |
| Average Basic Shares Outstanding | 0.99% | 1.00% | 0.97% | 0.87% | 0.78% |
| Average Diluted Shares Outstanding | 1.57% | 1.58% | 1.29% | 0.59% | 0.37% |
| Dividend Per Share | 1.44% | -2.89% | -2.89% | -3.60% | -3.60% |
| Payout Ratio | 0.40% | -0.10% | -0.30% | 1.15% | 1.24% |